Gilead Sciences | GILD - Cash And Equivalent

Stock Price
141.47
Daily Change
0.18 0.13%
Monthly
-6.39%
Yearly
31.59%
Q1 Forecast
140.61

Gilead Sciences reported $7.33B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
United Therapeutics USD 1.56B 217M Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025